Physician profile
Anjan Deka
NPI 1205126851
$9,030.32
in general payments reported to CMS, 2019-2025
22 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,953 · 2020: $136 · 2021: $195 · 2022: $366 · 2023: $516 · 2024: $739 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $6,654.47 | 2019 | |
| Shockwave Medical, INC | $467.16 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $262.32 | 2023-2025 | Watchman Flx, Avvigo Guidance System |
| Cardiovascular Systems INC. | $233.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $202.46 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $181.94 | 2020-2025 | Lifevest |
| Abbott Laboratories | $150.48 | 2019-2024 | Mitraclip, Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $143.67 | 2022-2025 | Camzyos, Eliquis |
| Janssen Scientific Affairs, LLC | $132.80 | 2024 | Xarelto |
| Edwards Lifesciences Corporation | $121.69 | 2021-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novartis Pharmaceuticals Corporation | $109.54 | 2023-2025 | |
| Philips North America LLC | $74.22 | 2023 | |
| Abiomed | $43.93 | 2021-2025 | |
| Angiodynamics, INC. | $42.92 | 2023 | Alphavac |
| Pfizer INC. | $38.81 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $36.64 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $33.19 | 2019 | |
| Medtronic, INC. | $27.25 | 2023 | Onyx Frontier |
| Actelion Pharmaceuticals US, INC. | $21.83 | 2023 | Uptravi, Opsumit |
| Kestra Medical Technology Services, INC. | $20.55 | 2024 | Assure Wcd |
| Amgen INC. | $16.02 | 2021 | |
| Cardiva Medical, INC. | $14.68 | 2023 | Cardiva Vascade 6/7f Vcs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjan Deka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.